Literature DB >> 8597751

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.

K A Jellinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8597751      PMCID： PMC2350538          DOI： 10.1136/bmj.312.7032.704

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Reliability of death certificate diagnoses.

Authors:  M A Moussa; M Z Shafie; M M Khogali; A M el-Sayed; T N Sugathan; G Cherian; A Z Abdel-Khalik; M T Garada; D Verma
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

2.  Mortality in patients with Parkinson's disease.

Authors:  L Wermuth; E N Stenager; E Stenager; J Boldsen
Journal:  Acta Neurol Scand       Date:  1995-07       Impact factor: 3.209

3.  Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.

Authors:  H Przuntek; D Welzel; E Blümner; W Danielczyk; H Letzel; H J Kaiser; P H Kraus; P Riederer; D Schwarzmann; H Wolf
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16
  4 in total
  3 in total

1.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

2.  Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

Authors:  Y Mizuno; T Kondo
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228

Review 3.  Monoamine oxidase inhibitors. A perspective on their use in the elderly.

Authors:  H P Volz; C H Gleiter
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.